Pharming (PHAR) EBIT Margin (2020 - 2025)
Historic EBIT Margin for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to 125.69%.
- Pharming's EBIT Margin rose 1202000.0% to 125.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.04%, marking a year-over-year increase of 138900.0%. This contributed to the annual value of 2.9% for FY2024, which is 7000.0% down from last year.
- Latest data reveals that Pharming reported EBIT Margin of 125.69% as of Q3 2025, which was up 1202000.0% from 2.21% recorded in Q2 2025.
- In the past 5 years, Pharming's EBIT Margin ranged from a high of 484.88% in Q1 2022 and a low of 29.35% during Q1 2024
- In the last 5 years, Pharming's EBIT Margin had a median value of 0.49% in 2021 and averaged 32.48%.
- In the last 5 years, Pharming's EBIT Margin crashed by -522000bps in 2021 and then skyrocketed by 4704600bps in 2022.
- Pharming's EBIT Margin (Quarter) stood at 15.69% in 2021, then fell by -19bps to 18.68% in 2022, then soared by 64bps to 6.63% in 2023, then crashed by -40bps to 9.3% in 2024, then skyrocketed by 1451bps to 125.69% in 2025.
- Its EBIT Margin was 125.69% in Q3 2025, compared to 2.21% in Q2 2025 and 8.91% in Q1 2025.